Interestingly, BI-5756 upregulated the expression of MHC I, MHC II, and the co-stimulatory molecule CD80 on A20 cells in a dose-dependent manner, indicating its potential as a promising anti-tumor agent that enhances T cell activation by increasing antigen presentation and co-stimulatory signaling on tumor cells (Figure 3C–E). Here, CD80 is linked to neoplasm.